Hims & Hers (NYSE: HIMS): A Buying Opportunity After the Recent Drop?

# **Hims & Hers (NYSE: HIMS): A Buying Opportunity After the Recent Drop?**  

Hims & Hers Health Inc. (HIMS) has seen a sharp drop in its stock price recently, leaving many investors wondering: **Is this the right time to buy?** If you're looking for a growth stock with strong potential, **this dip could be a great buying opportunity**. Let’s dive into what’s happening with HIMS and why now might be the perfect time to invest.  

---

## **Why Did Hims & Hers Stock Drop?**  

In the past few weeks, HIMS stock has taken a hit, dropping around **8-10%** from its recent highs. There are a few key reasons for this:  

1. **FDA’s Decision on Weight-Loss Drugs**  

   - The FDA announced that Eli Lilly’s weight-loss drug **Zepbound** is no longer in shortage.  

   - This news impacts companies like Hims & Hers, which had been offering compounded versions of similar medications.  

2. **Market Volatility & Profit-Taking**  

   - HIMS had a strong rally in early 2025, so some investors **took profits** when the stock reached high levels.  

   - The recent dip could be a normal **market correction** rather than a sign of deeper issues.  

3. **Short-Term Uncertainty**  

   - Some analysts are concerned about supply issues with GLP-1 drugs, a category of weight-loss and diabetes medications.  

   - However, Hims & Hers has already **announced plans to introduce new GLP-1 drugs** next year, which could drive future growth.  

---

## **Why This Drop Could Be a Buying Opportunity**  

Even though the stock has fallen, Hims & Hers remains a **fast-growing company with a bright future**. Here’s why this dip might be a good chance to **buy before it goes back up**:  

### **1. Strong Revenue Growth**  

- In Q3 2024, Hims & Hers reported a **77% revenue increase** to **$401.6 million**—a huge jump!  

- The company raised its **full-year revenue forecast** to nearly **$1.5 billion**, showing confidence in future growth.  

### **2. Expanding Services**  

- Hims & Hers just **acquired Trybe Labs**, a blood-testing company.  

- This will allow them to offer **at-home blood testing**, making their platform even more valuable.  

### **3. The Future of Telehealth is Bright**  

- More people prefer **online healthcare services** because they are **convenient and affordable**.  

- Hims & Hers is one of the **leaders in this space**, and demand for digital health services is expected to grow.  

---

## **Should You Buy HIMS Stock Now?**  

Many long-term investors **see dips like this as a buying opportunity**. The company’s strong revenue, expanding services, and growing market make it a **solid investment for the future**.  

**If you believe in the long-term potential of telehealth and Hims & Hers, now could be the perfect time to buy and wait for the stock to rebound!**  

**Buy the dip, hold, and watch it grow!**   

---

What do you think? Are you buying HIMS at these levels? Let me know in the comments!